But the FDA and the Centers for Disease Control and Prevention (CDC) released a safety notice on May 9 recommending that adults over 60 years old pause use of the vaccine due to fatal complications.

The CDC recommends the vaccine pause while it investigates “serious adverse events,” including neurologic and cardiac events.

The FDA and CDC recommended a pause in administering Ixchiq, a chikungunya vaccine, in adults ages 60 and above after 17 serious adverse events, including two deaths.  About 80,000 Ixchiq doses have ...

and the Centers for Disease Control and Prevention (CDC) are recommending a pause in the use of the chikungunya vaccine, called Ixchiq, for adults age 60 and older while they investigate reports of ...

Centres for Disease Control and Prevention (CDC) has issued an advisory urging American travellers over the age of 60 years ...